NPR News: Drugmaker Asks FDA To Rescind Rare Disease Status, Perks For COVID-19 Drug

Drugmaker Asks FDA To Rescind Rare Disease Status, Perks For COVID-19 Drug
By renouncing the special status, Gilead Sciences lets go of tax breaks, fee waivers and 7 years without generic competition for remdesivir, its experimental coronavirus treatment.

Read more on NPR